Citi lowered the firm’s price target on AbbVie (ABBV) to $230 from $235 and keeps a Neutral rating on the shares. The firm adjusted targets in the biopharma group as part of a Q4 preview. Estimates that are “beatable” and lower policy risk should create a favorable setup in 2026 for the group, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie Advances Early-Stage ABBV-722 Tablet Study, Underscoring Pipeline Momentum
- Looking for Exposure to UnitedHealth Stock (UNH) ahead of Q4 Earnings? Here’s How to Buy Without the Risk
- M&A News: Revolution Medicines (RVMD) Stock Plunges as Merck Ends Takeover Talks on Price Disagreement
- AbbVie price target raised to $275 from $270 at Berenberg
- Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Here’s How to Buy Without the Risk